Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection

Zeyu Xiao, Etgar Levy-Nissenbaum, Frank Alexis, Andrej Lupták, Benjamin A Teply, Juliana M. Chan, Jinjun Shi, Elise Digga, Judy Cheng, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Figure Persented: One of the major challenges in the development of targeted nanoparticles (NPs) for cancer therapy is to discover targeting ligands that allow for differential binding and uptake by the target cancer cells. Using prostate cancer (PCa) as a model disease, we developed a cell-uptake selection strategy to isolate PCa-specific internalizing 2′-O-methyl RNA aptamers (Apts) for NP incorporation. Twelve cycles of selection and counter-selection were done to obtain a panel of internalizing Apts, which can distinguish PCa cells from nonprostate and normal prostate cells. After Apt characterization, size minimization, and conjugation of the Apts with fluorescently labeled polymeric NPs, the NP-Apt conjugates exhibit PCa specificity and enhancement in cellular uptake when compared to nontargeted NPs lacking the internalizing Apts. Furthermore, when docetaxel, a chemotherapeutic agent used for the treatment of PCa, was encapsulated within the NP-Apt, a significant improvement in cytotoxicity was achieved in targeted PCa cells. Rather than isolating high-affinity Apts as reported in previous selection processes, our selection strategy was designed to enrich cancer cell-specific internalizing Apts. A similar cell-uptake selection strategy may be used to develop specific internalizing ligands for a myriad of other diseases and can potentially facilitate delivering various molecules, including drugs and siRNAs, into target cells.

Original languageEnglish (US)
Pages (from-to)696-704
Number of pages9
JournalACS Nano
Volume6
Issue number1
DOIs
StatePublished - Jan 24 2012

Fingerprint

therapy
cancer
engineering
Nanoparticles
nanoparticles
cells
docetaxel
Ligands
Cells
Nucleotide Aptamers
drugs
Cytotoxicity
RNA
ligands
conjugation
Molecules
affinity
counters
Pharmaceutical Preparations
cycles

Keywords

  • aptamer
  • in vitro selection
  • internalization
  • nanoparticles
  • targeted cancer therapy

ASJC Scopus subject areas

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Xiao, Z., Levy-Nissenbaum, E., Alexis, F., Lupták, A., Teply, B. A., Chan, J. M., ... Farokhzad, O. C. (2012). Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano, 6(1), 696-704. https://doi.org/10.1021/nn204165v

Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. / Xiao, Zeyu; Levy-Nissenbaum, Etgar; Alexis, Frank; Lupták, Andrej; Teply, Benjamin A; Chan, Juliana M.; Shi, Jinjun; Digga, Elise; Cheng, Judy; Langer, Robert; Farokhzad, Omid C.

In: ACS Nano, Vol. 6, No. 1, 24.01.2012, p. 696-704.

Research output: Contribution to journalArticle

Xiao, Z, Levy-Nissenbaum, E, Alexis, F, Lupták, A, Teply, BA, Chan, JM, Shi, J, Digga, E, Cheng, J, Langer, R & Farokhzad, OC 2012, 'Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection', ACS Nano, vol. 6, no. 1, pp. 696-704. https://doi.org/10.1021/nn204165v
Xiao, Zeyu ; Levy-Nissenbaum, Etgar ; Alexis, Frank ; Lupták, Andrej ; Teply, Benjamin A ; Chan, Juliana M. ; Shi, Jinjun ; Digga, Elise ; Cheng, Judy ; Langer, Robert ; Farokhzad, Omid C. / Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. In: ACS Nano. 2012 ; Vol. 6, No. 1. pp. 696-704.
@article{135539f416d6469eabc2c49d06dcdafe,
title = "Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection",
abstract = "Figure Persented: One of the major challenges in the development of targeted nanoparticles (NPs) for cancer therapy is to discover targeting ligands that allow for differential binding and uptake by the target cancer cells. Using prostate cancer (PCa) as a model disease, we developed a cell-uptake selection strategy to isolate PCa-specific internalizing 2′-O-methyl RNA aptamers (Apts) for NP incorporation. Twelve cycles of selection and counter-selection were done to obtain a panel of internalizing Apts, which can distinguish PCa cells from nonprostate and normal prostate cells. After Apt characterization, size minimization, and conjugation of the Apts with fluorescently labeled polymeric NPs, the NP-Apt conjugates exhibit PCa specificity and enhancement in cellular uptake when compared to nontargeted NPs lacking the internalizing Apts. Furthermore, when docetaxel, a chemotherapeutic agent used for the treatment of PCa, was encapsulated within the NP-Apt, a significant improvement in cytotoxicity was achieved in targeted PCa cells. Rather than isolating high-affinity Apts as reported in previous selection processes, our selection strategy was designed to enrich cancer cell-specific internalizing Apts. A similar cell-uptake selection strategy may be used to develop specific internalizing ligands for a myriad of other diseases and can potentially facilitate delivering various molecules, including drugs and siRNAs, into target cells.",
keywords = "aptamer, in vitro selection, internalization, nanoparticles, targeted cancer therapy",
author = "Zeyu Xiao and Etgar Levy-Nissenbaum and Frank Alexis and Andrej Lupt{\'a}k and Teply, {Benjamin A} and Chan, {Juliana M.} and Jinjun Shi and Elise Digga and Judy Cheng and Robert Langer and Farokhzad, {Omid C.}",
year = "2012",
month = "1",
day = "24",
doi = "10.1021/nn204165v",
language = "English (US)",
volume = "6",
pages = "696--704",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection

AU - Xiao, Zeyu

AU - Levy-Nissenbaum, Etgar

AU - Alexis, Frank

AU - Lupták, Andrej

AU - Teply, Benjamin A

AU - Chan, Juliana M.

AU - Shi, Jinjun

AU - Digga, Elise

AU - Cheng, Judy

AU - Langer, Robert

AU - Farokhzad, Omid C.

PY - 2012/1/24

Y1 - 2012/1/24

N2 - Figure Persented: One of the major challenges in the development of targeted nanoparticles (NPs) for cancer therapy is to discover targeting ligands that allow for differential binding and uptake by the target cancer cells. Using prostate cancer (PCa) as a model disease, we developed a cell-uptake selection strategy to isolate PCa-specific internalizing 2′-O-methyl RNA aptamers (Apts) for NP incorporation. Twelve cycles of selection and counter-selection were done to obtain a panel of internalizing Apts, which can distinguish PCa cells from nonprostate and normal prostate cells. After Apt characterization, size minimization, and conjugation of the Apts with fluorescently labeled polymeric NPs, the NP-Apt conjugates exhibit PCa specificity and enhancement in cellular uptake when compared to nontargeted NPs lacking the internalizing Apts. Furthermore, when docetaxel, a chemotherapeutic agent used for the treatment of PCa, was encapsulated within the NP-Apt, a significant improvement in cytotoxicity was achieved in targeted PCa cells. Rather than isolating high-affinity Apts as reported in previous selection processes, our selection strategy was designed to enrich cancer cell-specific internalizing Apts. A similar cell-uptake selection strategy may be used to develop specific internalizing ligands for a myriad of other diseases and can potentially facilitate delivering various molecules, including drugs and siRNAs, into target cells.

AB - Figure Persented: One of the major challenges in the development of targeted nanoparticles (NPs) for cancer therapy is to discover targeting ligands that allow for differential binding and uptake by the target cancer cells. Using prostate cancer (PCa) as a model disease, we developed a cell-uptake selection strategy to isolate PCa-specific internalizing 2′-O-methyl RNA aptamers (Apts) for NP incorporation. Twelve cycles of selection and counter-selection were done to obtain a panel of internalizing Apts, which can distinguish PCa cells from nonprostate and normal prostate cells. After Apt characterization, size minimization, and conjugation of the Apts with fluorescently labeled polymeric NPs, the NP-Apt conjugates exhibit PCa specificity and enhancement in cellular uptake when compared to nontargeted NPs lacking the internalizing Apts. Furthermore, when docetaxel, a chemotherapeutic agent used for the treatment of PCa, was encapsulated within the NP-Apt, a significant improvement in cytotoxicity was achieved in targeted PCa cells. Rather than isolating high-affinity Apts as reported in previous selection processes, our selection strategy was designed to enrich cancer cell-specific internalizing Apts. A similar cell-uptake selection strategy may be used to develop specific internalizing ligands for a myriad of other diseases and can potentially facilitate delivering various molecules, including drugs and siRNAs, into target cells.

KW - aptamer

KW - in vitro selection

KW - internalization

KW - nanoparticles

KW - targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=84856153806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856153806&partnerID=8YFLogxK

U2 - 10.1021/nn204165v

DO - 10.1021/nn204165v

M3 - Article

VL - 6

SP - 696

EP - 704

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 1

ER -